Molecular biomarkers in HNSCC: Prognostic and therapeutic implications

Expert Review of Anticancer Therapy

Volumn 1, Issue 1, 2001, Pages 116-124

  Hussein, Mohamed R ^a   Cullen, Kevin ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Bcl 2; c erb B2; Chemoprevention; Cyclin D1; Head and neck cancer; IMC C225; ONYX 015; p53; Telomerase

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CATHEPSIN D; CELL CYCLE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GLUTATHIONE; GROWTH FACTOR; INITIATION FACTOR; INTEGRIN; LAMININ; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SCLEROPROTEIN; SYNDECAN; TELOMERASE; THYMIDYLATE SYNTHASE; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; COST OF ILLNESS; DRUG TARGETING; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MORBIDITY; ONCOGENE C ERB; OUTCOMES RESEARCH; PERFORMANCE; PREDICTION; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0035557935     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.1.116     Document Type: Review

References (79)

1. Estimates of the worldwide incidence of eighteen major cancers in 1985
2. Genetic imbalances with impact on survival in head and neck cancer patients
3. 1 overexpression
4. Two regions of homozygosity on chromosome 3p in squamous cell carcinoma of the head and neck: Comparison with cytogenetic analysis
5. Loss of heterozygosity on chromosome 2q: Possibly a poor prognostic factor in head and neck cancer
6. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma
7. 9p21 deletion correlates with recurrence in head and neck cancer
8. Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers
9. Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer
10. Expression of c-erb B-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilaginous framework and prognosis
11. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression
12. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
13. Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse
14. Therapeutic application of anti-growth factor receptor antibodies
15. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies
16. Monoclonal antibody (Moab) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens
17. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo
18. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer
19. Frequent mutation of p16 in squamous cell carcinoma of the head and neck
20. p16 mutation frequency and clinical correlation in head and neck cancer
21. Induction of WAF1/CIP1 by a p53-independent pathway
22. Induction of WAF1/CIP1 by a p53-independent pathway
23. WAF1/CIP1 expression by p53-independent pathways
24. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer
25. WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus
26. WAF1/CIP1, p53 and bcl-2 in laryngeal squamous cell carcinoma
27. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma
28. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma
29. 1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan
30. 1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes
31. Mutation of p53 in squamous cell cancer of the head and neck: Relationship to tumor cell proliferation
32. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck
33. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer
34. Prognostic significance of p53 gene mutations in laryngeal cancer
35. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck
36. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
37. Prognostic value of p53, glutathione S-transferase π and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer
38. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx
39. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
40. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial
41. Phase II trial of intratumoral Administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
42. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
43. Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues
44. Clinical usefulness of telomerase assay for the detection of lymph node metastasis in patients with oral malignancy
45. Telomerase activity in oral cancer
46. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
47. Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl-2 and bax protein expression
48. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck
49. Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas
50. The prognostic value of spontaneous apoptosis, Bax, Bcl-2 and p53 in oral squamous cell carcinoma of the tongue
51. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma
52. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells
53. Angiogenesis: Prognostic significance in laryngeal cancer
54. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer
55. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas
56. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
57. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: Its association with tumor progression and p53 gene status
58. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma
59. Vascular endothelial growth factor as a target for antiangiogenic therapy
60. Expression of integrins in squamous cell carcinoma of the oral cavity. Correlations with tumor invasion and metastasis
61. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin 5
62. Clinicopathologic significance of laminin-5γ2 chain expression in squamous cell carcinoma of the tongue: Immunohistochemical analysis of 67 lesions
63. Syndecan-1 expression has prognostic significance in head and neck carcinoma
64. Predictive value of cathepsin-D for cervical lymph node metastasis in head and neck squamous cell carcinoma
65. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer
66. Immunohistochemical analysis and prognostic value of cathepsin D determination in laryngeal squamous cell carcinoma
67. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer
68. Expression of E-cadherin is associated with squamous differentiation in squamous cell carcinomas
69. Prediction of occult neck metastases in laryngeal carcinoma: Role of proliferating cell nuclear antigen, MIB-1 and E-cadherin immunohistochemical determination
70. Cytoplasmic accumulation of α-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma
71. Concentration of free hCGβ subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx
72. p53 serum antibodies as prognostic indicator in head and neck cancer
73. p53 expressions: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
74. A new prognostic indicator for head and neck cancer - p53 serum antibodies?
75. Serum p53 autoantibodies in the follow-up of head and neck cancer patients
76. Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells
77. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer
78. Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines
79. Glutathione content but not glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines